Table 5. Correlation of FLT3 plasma... | American Society of Hematology

Table 5.

Correlation of FLT3 plasma inhibitory activity, in vitro cytotoxic response, and clinical response to lestaurtinib

Patient no.	FLT3 mutation status	Residual FLT3 phosphorylation (plasma inhibitory activity), %*	MTS assay IC₅₀, nM†	Clinical response
1	WT	22.6	40	NR
2	WT	20.1	26	NR
10	WT	17.6	10	NR
15	ITD	7.2	2	HR
18	WT	0.0	> 150	NR
19	PM	2.0	2	HR
22	WT	3.7	> 150	NR
24	WT	13.3	> 150	PD
25	PM	1.8	> 150	PD
29	WT	3.7	> 150	PD

Patient no.	FLT3 mutation status	Residual FLT3 phosphorylation (plasma inhibitory activity), %*	MTS assay IC₅₀, nM†	Clinical response
1	WT	22.6	40	NR
2	WT	20.1	26	NR
10	WT	17.6	10	NR
15	ITD	7.2	2	HR
18	WT	0.0	> 150	NR
19	PM	2.0	2	HR
22	WT	3.7	> 150	NR
24	WT	13.3	> 150	PD
25	PM	1.8	> 150	PD
29	WT	3.7	> 150	PD

Maximal trough FLT3 plasma inhibitory activity at a lestaurtinib dose of 60 mg twice daily as measured by ex vivo bioassay.

Lestaurtinib concentration resulting in 50% in vitro cell death following 72-hour incubation.